Integrated Biopharma INTEL Bond

INBPDelisted Stock  USD 0.33  0.00  0.00%   
Integrated Biopharma holds a debt-to-equity ratio of 0.11. . Integrated Biopharma's financial risk is the risk to Integrated Biopharma stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Integrated Biopharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Integrated Biopharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Integrated OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Integrated Biopharma's stakeholders.
For most companies, including Integrated Biopharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Integrated Biopharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Integrated Biopharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
View Bond Profile
Given the importance of Integrated Biopharma's capital structure, the first step in the capital decision process is for the management of Integrated Biopharma to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Integrated Biopharma to issue bonds at a reasonable cost.
Popular NameIntegrated Biopharma INTEL P 49
SpecializationPackaged Foods
Equity ISIN CodeUS45811V1052
Bond Issue ISIN CodeUS458140AT73
S&P Rating
Others
Maturity DateOthers
Issuance DateOthers
View All Integrated Biopharma Outstanding Bonds

Integrated Biopharma Outstanding Bond Obligations

Dana 575 percentUS235822AB96Details
Volcan Compania MineraUSP98047AC08Details
Boeing Co 2196US097023DG73Details
INTEL P 315US458140AX85Details
INTEL P 41US458140AY68Details
Intel 245 percentUS458140BH27Details
INTEL P 3734US458140BG44Details
INTEL P 4US458140AN04Details
INTEL P 48US458140AK64Details
INTEL P 41US458140AV20Details
INTEL P 49US458140AT73Details
INTEL P 26US458140AU47Details
INTEL P 37US458140AS90Details
INTEL P 425US458140AP51Details
INTC 505 05 AUG 62US458140CC21Details
INTC 4875 10 FEB 26US458140CD04Details
INTC 415 05 AUG 32US458140CA64Details
INTC 49 05 AUG 52US458140CB48Details
INTC 59 10 FEB 63US458140CK47Details
INTC 57 10 FEB 53US458140CJ73Details
INTC 52 10 FEB 33US458140CG35Details
INTC 5625 10 FEB 43US458140CH18Details
INTC 4875 10 FEB 28US458140CE86Details
INTC 5125 10 FEB 30US458140CF51Details
INTEL PORATIONUS458140BQ26Details
INTEL PORATIONUS458140BR09Details
INTEL PORATIONUS458140BP43Details
INTEL PORATIONUS458140BM12Details
INTEL PORATIONUS458140BN94Details
Intel 31 percentUS458140BK55Details
Intel 325 percentUS458140BJ82Details
INTEL PORATIONUS458140BL39Details
INTC 4 05 AUG 29US458140BZ25Details
INTC 375 05 AUG 27US458140BY59Details
INTC 305 12 AUG 51US458140BW93Details
INTC 32 12 AUG 61US458140BX76Details
INTC 2 12 AUG 31US458140BU38Details
INTC 28 12 AUG 41US458140BV11Details
INTC 16 12 AUG 28US458140BT64Details
MPLX LP 52US55336VAL45Details
International Game TechnologyUS460599AD57Details
BNP Paribas FRNUSF1R15XK367Details
Morgan Stanley 3971US61744YAL20Details
MGM Resorts InternationalUS552953CD18Details
Valero Energy PartnersUS91914JAA07Details

Understaning Integrated Biopharma Use of Financial Leverage

Integrated Biopharma's financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Integrated Biopharma's current equity. If creditors own a majority of Integrated Biopharma's assets, the company is considered highly leveraged. Understanding the composition and structure of Integrated Biopharma's outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.
Please read more on our technical analysis page.

Pair Trading with Integrated Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integrated Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrated Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Integrated OTC Stock

  0.56LW Lamb Weston HoldingsPairCorr
  0.43LSF Laird Superfood Upward RallyPairCorr
  0.37FRPT FreshpetPairCorr
  0.34K KellanovaPairCorr
The ability to find closely correlated positions to Integrated Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Integrated Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Integrated Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Integrated Biopharma to buy it.
The correlation of Integrated Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Integrated Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Integrated Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Integrated Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Consideration for investing in Integrated OTC Stock

If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.